NABRIVA THERAPEUTICS PLC (NBRV)

IE000OZRGNV6 - Common Stock

1.42  0 (0%)

After market: 1.3986 -0.02 (-1.51%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027
Revenue
YoY % growth
5.03M
-46.94%		28.895M
474.45%		36.935M
27.82%		72.189M
95.45%
EBITDA
YoY % growth
-65.7M
16.93%		-48.172M
26.68%		-50.956M
-5.78%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
-66.12M
16.82%		-48.528M
26.61%		-51.173M
-5.45%		-31.805M
37.85%
Operating Margin
-1,314.51%-167.95%-138.55%-44.06%
EPS
YoY % growth
-147.75
47.23%		-27.03
81.71%		N/A-8.94

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q2 / 23 Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-2.35
47.87%
Revenue
Q2Q % growth		17.748M
93.10%
EBITDA
Q2Q % growth		N/AN/AN/A
EBIT
Q2Q % growth		-8.185M
21.29%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2022
Q2Q % growth		 -4.21
-701.90%		-4.11-0.10-2.55%
Q2 2022
Q2Q % growth		 -4.50
37.93%		-5.100.6011.76%
Q1 2022
Q2Q % growth		 -5.00
62.26%		-4.85-0.16-3.20%
Q4 2021
Q2Q % growth		 -6.00
78.38%		-4.85-1.16-23.84%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2023
Q2Q % growth		 7.59M
-5.36%		13.158M-5.568M-42.32%
Q4 2022
Q2Q % growth		 10.571M
14.15%		11.258M-687K-6.10%
Q3 2022
Q2Q % growth		 9.153M
3.28%		10.889M-1.736M-15.94%
Q2 2022
Q2Q % growth		 9.191M
11.50%		8.701M490K5.63%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% 0%
Revenue0% 0% 0% 0%